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Abstract 
Background: The early recognition and management of sepsis improves outcomes. Biomarkers may help in identify‑
ing earlier sub‑clinical signs of sepsis. We explored the potential of serial measurements of C‑reactive protein (CRP), 
procalcitonin (PCT) and pancreatic stone protein (PSP) for the early recognition of sepsis in patients hospitalized in 
the intensive care unit (ICU).
Methods: This was a multicentric international prospective observational clinical study conducted in 14 ICUs in 
France, Switzerland, Italy, and the United Kingdom. Adult ICU patients at risk of nosocomial sepsis were included. A 
biomarker‑blinded adjudication committee identified sepsis events and the days on which they began. The associa‑
tion of clinical sepsis diagnoses with the trajectories of PSP, CRP, and PCT in the 3 days preceding these diagnoses of 
sepsis were tested for markers of early sepsis detection. The performance of the biomarkers in sepsis diagnosis was 
assessed by receiver operating characteristic (ROC) analysis.
Results: Of the 243 patients included, 53 developed nosocomial sepsis after a median of 6 days (interquartile range, 
3–8 days). Clinical sepsis diagnosis was associated with an increase in biomarkers value over the 3 days preceding 
this diagnosis [PSP (p = 0.003), PCT (p = 0.025) and CRP (p = 0.009)]. PSP started to increase 5 days before the clinical 
diagnosis of sepsis, PCT 3 and CRP 2 days, respectively. The area under the ROC curve at the time of clinical sepsis was 
similar for all markers (PSP, 0.75; CRP, 0.77; PCT, 0.75).
Conclusions: While the diagnostic accuracy of PSP, CRP and PCT for sepsis were similar in this cohort, serial PSP 
measurement demonstrated an increase of this marker the days preceding the onset of signs necessary to clinical 
diagnose sepsis. This observation justifies further evaluation of the potential clinical benefit of serial PSP measurement 
in the management of critically ill patients developing nosocomial sepsis.
© The Author(s) 2021. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, 
adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and 
the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material 
in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material 
is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds 
the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://crea‑
tivecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdo‑
main/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Open Access
*Correspondence:  bruno.francois@chu‑limoges.fr
†Philippe Eggimann and Bruno François have contributed equally to this 
work
2 Medical‑Surgical Intensive Care Unit, Inserm CIC 1435 and UMR 1092, 
Dupuytren Teaching Hospital, Limoges, France
Full list of author information is available at the end of the article
Page 2 of 9Pugin et al. Crit Care          (2021) 25:151 
Background
Sepsis, if not recognized and managed early, may 
evolve rapidly into life-threatening septic shock and 
multiple organ failure [1–3]. Sepsis and septic shock 
remain challenging global health problems associated 
with persistently high morbidity and mortality; in 2017, 
an estimated 48.9 million cases of sepsis were recorded 
worldwide, with 11.0 million related deaths, represent-
ing one-fifth of all causes of death [4]. Accordingly, 
guidelines systematically emphasize the early recogni-
tion and aggressive management of sepsis, with com-
bined early antibiotic treatment and support to prevent 
organ dysfunction [1, 5, 6]. Currently, the confirmation 
of sepsis diagnosis is based largely on nonspecific clini-
cal signs, laboratory findings and medical scores, which 
are usually obtained after sepsis onset. Despite exten-
sive research, no biomarker has been identified with 
the capacity to detect sepsis quickly enough and with a 
high degree of diagnostic accuracy [7]. C-reactive pro-
tein (CRP) is a well characterized inflammatory marker 
widely used to help in the diagnosis of infection. Pro-
calcitonin (PCT) has been extensively evaluated in the 
last 20 years as a marker of bacteremia. Even if CRP and 
PCT are commonly used in the context of the diagnosis 
of sepsis, both have shown suboptimal performance [8].
Pancreatic stone protein (PSP) is a C-type lectin 
protein that triggers polymorphonuclear cell activa-
tion and has shown proinflammatory activity in  vitro 
[9]. In an unselected cohort of critically ill adults, PSP 
was found to be superior to PCT and other sepsis bio-
markers for the accurate identification of sepsis [10]. 
An increase in PSP level preceding the development of 
sepsis has recently been demonstrated in a cohort of 
severely burnt patient [11]. The diagnostic performance 
of PSP, alone and in combination with other markers or 
clinical scores, was evaluated further in several studies 
conducted in adults, children, and neonates, in both, 
intensive care units (ICUs) and emergency departments 
[12]. In contrast to PCT and CRP, PSP was found to 
be a prognostic marker for ICU mortality [13–15]. In 
addition, point-of-care measurement of CRP and PCT 
is not common in ICU, while PSP can be measured 
with a ‘point-of-care’ device within 5 min using a single 
drop of whole blood [16], leading the way for simple, 
on-demand, around-the-clock, serial biomarker assess-
ments instead of one-off measurements upon the clini-
cal suspicion of sepsis.
We hypothesized that timely identification of changes 
in biomarker levels may help identify sepsis before the 
onset of clinical signs. We therefore designed a multicen-
tric international prospective blind observational clinical 
study to explore the ability of serial PSP measurements 
to identify nosocomial sepsis before the onset of clini-
cal signs required to clinically diagnose sepsis in an adult 
ICU population, and compare it with CRP and PCT.
Study design and methods
Study design
This multicentric biomarker-blinded prospective obser-
vational clinical study was conducted in 14 ICUs in 
France, Switzerland, Italy, and the United Kingdom, see 
Additional file  1: Table  1. Approval was obtained from 
the ethics committees of all participating sites. The study 
was registered at ClinicalTrials.gov (no. NCT03474809).
Patient population
All patients older than 18 years old admitted to the ICU 
and expected to stay at least 7 days and/or to be mechan-
ically ventilated for at least 5 consecutive days were 
screened for study inclusion (Additional file  1:Table  2). 
Patients with a clinical diagnosis of sepsis or suspicion 
of sepsis at the admission were not included. Written 
informed consent to participation and any study-related 
assessment was obtained from all patients before their 
inclusion in the study. Written informed consent was 
obtained according to the specific requirements of each 
center’s ethics committee.
At least 40 patients who developed sepsis after study 
enrolment were planned to be included. Based on 
recently published data [17–19], the expected incidence 
of sepsis in the targeted ICU population was estimated 
conservatively to be 15%. This value corresponded to a 
sample of 267 patients, to which we added 10% to com-
pensate for withdrawal and loss to follow-up.
Trial procedure and definitions
Patients were managed according to the centers’ stand-
ard clinical practices, including those for the diagnosis, 
assessment, and treatment of sepsis. Blood samples were 
collected daily for biomarker (PCT, CRP, and PSP) meas-
urements. Patients were followed until death or discharge 
from the ICU or for 30  days, whichever occurred first. 
The Sepsis-3 criteria were used to define sepsis [1], and 
microbiological procedures were performed to diagnose 
Trial registration The study has been registered at ClinicalTrials.gov (no. NCT03474809), on March 16, 2018. https:// 
www. clini caltr ials. gov/ ct2/ show/ NCT03 474809? term= NCT03 47480 9& draw= 2& rank=1.
Keywords: Pancreatic stone protein, Sepsis, Diagnostic, Procalcitonin, C‑reactive protein, Biomarker
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infections responsible for sepsis according to local 
protocol.
Measurement of biomarkers
Daily PSP levels were determined at the end of the study 
period with the CE-marked IVD PSP capsule on the 
point-of-care abioSCOPE® device (Abionic SA; Addi-
tional file 2: Figure 1). The 5th and 95th percentiles of PSP 
values in healthy adults are 25.0 to 60.7 ng/ml (median: 
41.7 ng/ml) (Abionic internal data). CRP and PCT meas-
urements were performed by a central laboratory using a 
Tina-quant® C-Reactive Protein Gen.3 (Roche Diagnos-
tics) and a Liaison® Brahms PCT® for PCT (DiaSorin), 
respectively. All instruments were used according to the 
manufacturers’ instructions. The upper limit of the nor-
mal range of the CRP assay is 5  mg/l, and of the PCT 
assay 0.1 ng/ml, as per the manufacturer’s information.
External adjudication committee
An independent endpoint adjudication committee (EAC) 
composed of three ICU experts was formed. Two non-
chair EAC members retrospectively and independently 
reviewed case report forms for each patient and deter-
mined whether a septic event had occurred during the 
patient’s ICU stay (including on the day of inclusion), 
and on which day it started. Day 0 sepsis was determined 
using all information collected in the study’s eCRF and 
in accordance with the proposal published by Lambden 
et  al. [20]. Discordant determinations were arbitrated 
by the EAC chair. The EAC had access to all case report 
forms, including results of all microbiological investiga-
tions, CRP and PCT measurements taken in the ICUs as 
part of standard care, but was blinded to centrally meas-
ured PSP, PCT, and CRP levels and the investigators’ 
diagnoses of sepsis.
Patient‑related data
Data collected at the time of inclusion were: demographic 
characteristics, reason for ICU admission, medical his-
tory, and Charlson comorbidity index. Additional clinical 
data were collected on day 1 and daily thereafter when 
measurements were performed as part of standard care; 
these data included vital signs (temperature, heart rate, 
and blood pressure), Sequential Organ Failure Assess-
ment (SOFA) score,  PaO2/FiO2 ratio, hematological data, 
clinical chemistry parameters, need for organ support 
(ventilation and use of vasoactive drugs) and microbio-
logical data. In addition to the collection of data on anti-
biotic treatments (drug name, dose, schedule, route, and 
indication), meticulous assessments for sepsis detection 
were carried out daily until ICU discharge, death, with-
drawal, or day 30, whichever came first.
Statistical analyses
Discrete values are described as counts (percentages) and 
continuous variables are described as means with stand-
ard errors or medians with interquartile ranges (IQRs), as 
appropriate. The missing biomarker values were imputed 
by carrying the last observation forward, and multiple 
consecutive missing values were reported as missing. 
Based on EAC decisions, the patients were allocated to 
sepsis (a septic event occurred during the study period) 
or no-sepsis (no septic event during the study period) 
groups. In the sepsis group, the event day was set as the 
day on which the first septic events began, according to 
the EAC. In the no-sepsis group, the event day was set 
to day 7 of patients’ ICU stays, when more than 50% of 
adjudicated septic events occurred, or the days of dis-
charge for patients with ICU stays of fewer than 7 days. 
Biomarkers average trajectories were visualized accord-
ingly. All statistical analyses were performed using R ver-
sion 4.0.2.
Biomarkers dynamics and progression toward sepsis
To explore the dynamics of serial biomarker meas-
urement throughout the study period, we modeled 
biomarker courses in the 3 days prior to EAC sepsis diag-
noses by fitting a linear mixed-effect model with PSP, 
CRP, and PCT as response and the following explana-
tory variables: patient-specific random effect, group, 
day-to-event and group by day-to-event interaction 
as fixed-effects (estimates are provided in Additional 
file 1: Table 3). According to Van Breukelen [21] “testing 
absence of group by time interaction is equivalent to test-
ing the hypothesis of no group effect on the change” in a 
response variable over days.
Assessment of biomarker accuracy in diagnosing sepsis
The joint performance of the biomarkers in the diagno-
sis of sepsis on the day it occurred as per EAC decision 
was assessed using receiving operating characteristic 
(ROC) analysis. To account for differences among study 
sites and incidences of nosocomial sepsis, a linear mixed-
effects logistic regression model was used with the center 
serving as a random intercept and biomarkers serving as 
fixed events to determine diagnostic accuracy, sensitivity, 
specificity, and the positive and negative likelihood ratios 
(estimates are provided in Additional file 1: Table 4) [22]. 
Cut-off values of PSP, CRP and PCT have been estimated 
without adjusting for center-effect.”
Results
Baseline characteristics of the study population
From June 2018 to March 2019, 297 patients were 
enrolled in this study. The mean patients recruited per 
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site was 21, and the median number was 15 (IQR: 8 to 23) 
(Additional file  1: Table  1b). Fifty-four of these patients 
were excluded from the analysis due to the presence of 
infection and/or sepsis at the time of inclusion as adju-
dicated by the EAC (n = 33), ICU stays < 48  h (n = 15), 
withdrawal (n = 5), and screening failure (n = 1) (Fig. 1). 
The characteristics of the remaining 243 patients are 
summarized in Table 1. The cohort contained 153 (63%) 
men and had a median age of 65  years (IQR: 54 to 73) 
and a median SOFA score of 6 (IQR: 5 to 9) at the time of 
admission. The most common comorbidities were cancer 
(16%) and heart (15%), pulmonary (13%), renal (12%), and 
hepatic (7%) diseases. Vasopressors were administered to 
39% of patients, and 77% of patients required mechani-
cal ventilation. The main reasons for ICU admission were 
acute central nervous system diseases (39%), cardiovas-
cular diseases (31%), and abdominal/digestive conditions 
(19%; Table  1). The median ICU length of stay of the 
entire cohort was 9  days (IQR: 6 to 17); 7  days (IQR: 5 
to 13  days) for the “no-sepsis” patients and 21  days for 
patients who developed sepsis (IQR: 14 to 27 days). ICU 
mortality rate in the study cohort was 16%. The baseline 
clinical characteristics of patients who did and did not 
develop sepsis during the study period were similar.
According to the EAC decisions, 21.8% (n = 53) of the 
patients developed sepsis and 78.2% (n = 190) did not. 
The EAC chair arbitrated disagreements about sepsis 
presence/absence and day of initiation in 31% of cases. 
Two thirds of them concerned the date of onset of the 
sepsis and were resolved by the chair of the committee. 
The median interval from study inclusion to sepsis devel-
opment was 6 days (IQR: 3 to 8 days). The characteristics 
of patients who developed sepsis are provided in Table 2. 
Sepsis originated most frequently from respiratory tract 
infections (62%), followed by bloodstream infections 
(11%) and urinary tract (9%) infections.
Time courses of biomarkers for sepsis prediction
The time courses of biomarkers until sepsis (“sepsis” 
group), and until day 7 or discharge for ICU stays of 
fewer than 7 days (“no-sepsis” group) are shown in Fig. 2. 
All biomarker values increased for several days before 
the clinical diagnosis of sepsis (PSP, 5 days; PCT, 3 days; 
CRP, 2  days). Clinical sepsis diagnosis was associated 
with an increase in biomarkers over the 3 days preceding 
this diagnosis: PSP (p = 0.003), PCT (p = 0.025) and CRP 
(p = 0.009). Furthermore, estimates of exploratory vari-
ables are provided in the Additional file 1: Table 3.
Accuracy of individual biomarkers and their combination 
in sepsis diagnosis
Areas under receiver operating characteristic curves 
(AUROCCs) on the day of sepsis diagnosis according to 
the blinded EAC were similar for all three biomarkers 
{PSP, 0.75 [95% confidence interval (CI) 0.67–0.82]; CRP, 
0.77 [95% CI 0.69–0.84] PCT, 0.75 [95% CI 0.68–0.83]} 
(Table  3 and Additional file  3: Figure  2). The combined 
use of PSP with CRP improved the accuracy to 0.79 (95% 
CI 0.72–0.86). The addition of PCT to this combination 
did not further improve the accuracy or sensitivity, and 
only marginally improved the specificity. Estimates for 
the mixed-effects models for which the diagnostic per-
formances are reported in Table  3 are provided in the 
Additional file  1: Table  4. Estimated cut-off values of 
Fig. 1 Flow of patient enrollment. There were 4 (0.14%) missing values for PSP (0; 0.0% after imputation), 8 (0.35%) for CRP (1; 0.04% after 
imputation) and 8 (0.28%) for PCT (2; 0.07% after imputation). CRP C‑reactive protein, EAC endpoint adjudication committee, ICU intensive care unit, 
PCT procalcitonin, PSP pancreatic stone protein
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biomarkers are 290.5 ng/ml for PSP, 167.2 mg/l for CRP 
and 0.94 ng/ml for PCT.
Discussion
This prospective multicentric study evaluated the poten-
tial of serial host protein biomarkers measurement, in 
particular the relatively new marker PSP, for the early 
identification of nosocomial sepsis in ICU patients. In 
the study cohort of critically ill patients at high risk of 
complications, in which one in five developed sepsis, the 
baseline clinical characteristics, including severity scores 
and the need for mechanical ventilation and vasopressor 
support, were similar among patients who did and did 
not develop sepsis. The main novel finding of this study 
is the significant association of the clinical diagnosis of 
sepsis with the continuous increase in the PSP level in 
the 3  days before this diagnosis. This association cor-
roborates the initial description of this particularity of 
PSP [9], recently confirmed in a cohort of patients with 
severe burns, in which PSP levels increased constantly in 
the days preceding sepsis and this increase was greater in 
patients with septic shock [11, 23].
In addition, this study confirmed that the accuracy of 
clinical sepsis diagnosis based on PSP values was simi-
lar to that of diagnoses based on PCT and CRP values. 
Cut-off values for PSP the day of sepsis were however 
higher than usually reported in the literature, which is 
certainly due to the characteristics of the patients we 
included that differ from other studies with PSP in which 
it was evaluated at time of sepsis or suspected sepsis at 
admission. In an unselected population of critically ill 
patients, the use of PSP values to distinguish sepsis from 
non-infectious systemic inflammatory response syn-
drome (SIRS) at the time of ICU or high-dependency 
care admission was more accurate than the use of PCT 
values [10] was. Furthermore, a recent meta-analysis of 
data from 631 ICU patients, of whom 371 had infections 
or sepsis, confirmed that these conditions could be iden-
tified accurately based on PSP values [AUROCC = 0.81, 
slightly superior to those for PCT (0.78) and CRP (0.77)]. 
The combined use of PSP and CRP values increased this 
accuracy (AUROCC = 0.90) (Prazak J. et  al., e-ISICEM, 
Sept. 15-18.2020), similarly to what was observed in this 
study where the combination of CRP and PSP increased 
Table 1 Clinical characteristics of patients at the time of study admission (day 1 of intensive care unit stay) for the entire cohort and 
for the two sub‑groups “sepsis” and “no‑sepsis”
The following tests were performed: 1Chi2; 2Wilcoxon; 3Fisher’s exact. Statistical significance was set a p value ≤ 0.05
ICU intensive care unit, IQR interquartile range, SOFA sequential organ failure assessment, CNS central nervous system
Variable Modality/statistics Total (N = 243) No Sepsis (N = 190) Sepsis (N = 53) p value
Gender F 90/243 (37%) 77/190 (41%) 13/53 (25%) 0.0331
M 153/243 (63%) 113/190 (59%) 40/53 (75%)
Age Median (Q1;Q3) 65.0 (54.0;73.0) 65 (54;72) 64 (55;73) 0.9152
SOFA score Median (Q1;Q3) 6 (5;9) 6 (4;9) 7 (5;9) 0.0402
Charlson score 0 51/243 (21%) 46/190 (24%) 5/53 (9%) 0.0551
1–2 84/243 (35%) 60/190 (32%) 24/53 (45%)
3–4 47/243 (19%) 34/190 (18%) 13/53 (25%)
5 and more 52/243 (21%) 42/190 (22%) 10/53 (19%)
Non‑reported Charlson score 9/243 (4%) 8/190 (4%) 1/53 (2%)
Reason for ICU admission CNS (trauma, stroke, haemorrhage) 94/243 (39%) 74/190 (39%) 20/53 (38%) 0.6573
Cardiovascular 76/243 (31%) 60/190 (32%) 16/53 (30%)
Abdominal/digestive 45/243 (19%) 32/190 (17%) 13/53 (25%)
Respiratory 18/243 (7%) 16/190 (8%) 2/53 (4%)
Metabolic 9/243 (4%) 7/190 (4%) 2/53 (4%)
ICU treatments Mechanical ventilation 187/243 (77%) 143/190 (75%) 44/53 (83%) 0.2361
Vasopressors 95/243 (39%) 69/190 (36%) 26/53 (49%) 0.1751
No‑reported vasopressors 16/243 (7%) 15/190 (8%) 1/53 (2%)
Comorbidities Cancer 40/243 (16%) 33/190 (17%) 7/53 (13%) 0.4301
Heart disease 35/243 (14%) 26/190 (14%) 9/53 (17%) 0.5901
Pulmonary disease 31/243 (13%) 26/190 (14%) 5/53 (9%) 0.3811
Renal disease 29/243 (12%) 23/190 (12%) 6/53 (11%) 0.8321
Liver disease 17/243 (7%) 12/190 (6%) 5/53 (9%) 0.5433
ICU length of stay Median (Q1;Q3) 9 (6;17) 7 (5;13) 21 (14;27) < 0.0012
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the accuracy to 0.79, although the overlap of the 95% 
confidence intervals preclude to draw a robust statement 
regarding the significance of this increase.
This study has several strengths. First, it is the first 
international multicentric prospective study in which 
a host protein blood biomarker, the PSP, was meas-
ured daily in an ICU setting for the early detection of 
nosocomial sepsis using a point-of-care device offer-
ing on-demand test results in less than 10 min. Second, 
nosocomial sepsis was diagnosed by an independ-
ent adjudication committee composed of intensivists 
blinded to biomarker results. Third, this study deter-
mined the accuracy of single and combined biomark-
ers in the diagnosis of nosocomial sepsis in critically 
ill patients. Fourth, we explored the performance of 
the biomarkers, but we could not strictly interpret the 
value of bedside measurements of PSP compared to 
test performed in the clinical laboratory. However, sev-
eral limitations of this study must be considered. Given 
its multicentric international design, the recruitment 
rate and sepsis incidence differed among study sites, 
in association with differences in preventive measures 
against nosocomial infection and sepsis development. 
In addition, although the expected number of patients 
who developed sepsis was reached, the low absolute 
number of sepsis events precluded subgroup analysis 
Table 2 Characteristics of patients in the sepsis group at the 
time of endpoint adjudication committee diagnosis of sepsis
PSP pancreatic stone protein, CRP C-reactive protein, PCT procalcitonin, IQR 
interquartile range, ICU intensive care unit, SOFA sequential organ failure 
assessment
Characteristics Sepsis
Number of patients (n) 53
Time interval of the clinical diagnosis of sepsis, 
median [IQR]
6 [3, 8]
SOFA score, median [IQR] 9 [6, 10]
ICU treatments (n, %)
 Mechanical ventilation 35 (66%)
 Non reported mechanical ventilation 14 (26%)
 Vasopressors 27 (51%)
 Non reported vasopressors 1 (2%)
Biomarkers
 PSP, median (ng/ml) [IQR] 205 [120.3, 621]
 CRP, median (mg/l) [IQR] 167.3 [77.8, 257.6]
 PCT, median (ng/ml) [IQR] 0.77 [0.2, 2.2]
 Site of infection (n, %) 47 (87%)
 Respiratory tract (n, %) 29 (62%)
 Bloodstream (n, %) 5 (11%)
 Renal urinary tract (n, %) 4 (9%)
 Abdominal (n, %) 3 (6%)
 Other (n, %) 6 (13%)
Fig. 2 Association of pancreatic stone protein, procalcitonin and 
C‑reactive protein increase with sepsis. Daily mean values ± standard 
errors of the mean for the sepsis group are from the 6 days preceding 
the endpoint adjudication committee diagnosis of sepsis. For the 
no‑sepsis group, day 0 was set as intensive care unit day 7 or the 
day of discharge for intensive care unit stays < 7 days. The p values 
are for the association of clinical sepsis diagnosis with a continuous 
biomarker increase in the preceding 3 days (pancreatic stone protein, 
p = 0.003; procalcitonin, p = 0.025; C‑reactive protein, p = 0.009). ns 
are numbers of observations per day and group. PSP pancreatic stone 
protein, PCT procalcitonin, CRP C‑reactive protein, EAC endpoint 
adjudication committee, ICU intensive care unit
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by site or country. Finally, this study was conducted 
with a subgroup of ICU patients who were expected 
to have prolonged ICU stays but were admitted free of 
infection, which precludes the extension of our obser-
vations to other settings, in particular for lower risk of 
developing nosocomial sepsis.
In the absence of an unambiguous definition of sep-
sis and highly accurate diagnostic tools the presence/
absence of sepsis at any given days of an ICU stay was 
adjudicated by an expert committee. Discordant results 
using such approach have already been reported and 
vary considerably within sepsis diagnosis subgroups 
and clinical question [24], 25]. In our study not only 
the presence or absence of sepsis was adjudicated but 
also the day of event: this additional parameter contrib-
uted to the rate of discordance observed, reflecting the 
diagnostic challenges that clinicians are facing for the 
timely diagnosis of sepsis.
The inclusion of a risk-stratification of patients, for 
example based on clinical score such as the SOFA and 
the Acute Physiology And Chronic Health Evaluation 
(APACHE) scores, or of algorithms offering pretest 
probability in such diagnostic strategies, would allow 
to define economically viable and clinically meaningful 
strategies to closely monitor patients who will benefit 
the most of such approaches. In respect to that, the fre-
quency of biomarkers measurement associated with the 
best clinical benefit remains to be established.
The clinical significance of an increase in the PSP 
level the days preceding the clinical diagnosis of sepsis 
may prompt changes in the management of patients at 
risk of nosocomial sepsis by triggering early diagnostic 
procedures and the timely establishment of appropri-
ate treatment, for example to identify the source of the 
infection and the pathogen, and to assess the clinical 
utility of preemptive antibiotic therapy. Future inter-
ventional studies should also include a benefit-risk 
ratio of serial measurement of PSP, with a particular 
emphasis on the impact of false positive tests leading 
to unnecessary and potentially harmful diagnostic and 
therapeutic procedures. The results of this study may 
serve as a robust early basis for future validation studies 
of such an innovative approach, including studies con-
ducted in wards outside of the ICU to determine how 
serial PSP measurement could enable early detection of 
sepsis before the onset of clinically overt symptoms in 
patients at risk.
Conclusions
The diagnostic accuracy of PSP, CRP and PCT for the 
diagnosis of sepsis at the time the EAC identified it were 
similar. Serial measurements of biomarker revealed that 
blood PSP levels increased incrementally 3  days before 
the clinical diagnosis of nosocomial sepsis in critically ill 
patients, potentially allowing the early detection of sep-
sis before the appearance of signs and symptoms. These 
results justify further evaluation of the potential of serial 
PSP measurement in the early diagnosis, management 
and clinical outcome of critically ill patients developing 
nosocomial sepsis.
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PCT 0.75 (0.68, 0.82) 0.72 (0.60, 0.84) 0.69 (0.62, 0.76) 0.41 (0.27, 0.64) 2.31 (1.75, 3.04)
PSP‑CRP 0.79 (0.72, 0.86) 0.72 (0.60, 0.84) 0.73 (0.67, 0.80) 0.39 (0.25, 0.60) 2.69 (2.00, 3.61)
PSP‑PCT 0.75 (0.68, 0.83) 0.76 (0.64, 0.87) 0.65 (0.58, 0.72) 0.38 (0.23, 0.61) 2.16 (1.68, 2.77)
CRP‑PCT 0.77 (0.70, 0.84) 0.68 (0.55, 0.81) 0.77 (0.71, 0.83) 0.42 (0.28, 0.62) 2.91 (2.11, 4.02)
CRP‑PCT‑PSP 0.79 (0.72, 0.86) 0.72 (0.60, 0.84) 0.74 (0.68, 0.81) 0.38 (0.25, 0.59) 2.81 (2.08, 3.79)
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Estimates for the mixed‑effects models for which the results are reported 
in Table 3.
Additional file 2: Figure 1. The abioSCOPE® device and its in vitro diag‑
nostic CAPSULE pancreatic stone protein.
Additional file 3: Figure 2. ROC curves for the diagnosis of sepsis at the 
time sepsis was clinically diagnosed by the EAC.
Acknowledgements
We are grateful to all the physicians, nursing staff, and patients who par‑
ticipated in this study. In particular, we would like to thank: Aurélie Perret 
and Philippe Montillier at the Hôpitaux Universitaires de Genève, Geneva, 
Switzerland; Paul Bourzeix, Céline Prevost, Ludmila Baudrillart, Alexandra Gay, 
Anne‑Aurore Duchambon, Fanny Mamert, Perrine Engel, Isabelle Herafa; 
Co‑investigators : Philippe Vignon, Arnaud Desachy, Marine Goudelin, Anne 
Laure Fedou, Bruno Evrard, Pauline Segouffin at the Dupuytren Teaching 
Hospital, Limoges, France; Antonella Potalivo, Francesca Facondini and Andrea 
Pazzini at the Ospedale Infermi Rimini, Rimini, Italy; Francesco Anniciello and 
Alessandra Belli at the Azienda Ospedaliera di Perugia, Perugia, Italy; Cédric 
Darreau, Patrice Tirot, Mickael Landais, Nicolas Chudeau, Marjorie Saint‑Martin, 
Jean‑Christophe Callahan and Alain Robert at the Centre hospitalier Le Mans, 
Le Mans, France; Josef Prazak, Sabine Berger and the team of Research Nurses 
at the Bern University Hospital, Bern, Switzerland; Niall MacCallum, Deborah 
Smyth, Georgia Bercades and Jung Ryu at the University College Hospital, 
London, United Kingdom; James McKinlay, Kathryn McIntosh, Harry Brown, 
Gokce Daysal, Jessica Welch, Paula Carvelli, Humyraa Aziz, Laura Montague, 
Justin Kirk‑Bayley and Lui Forni at the Royal Surrey County Hospital, Guildford, 
United Kingdom; Tiziana Casalicchio an Giulia Arena at the Ospedale San Gio‑
vanni Bosco, Torino, Italy; Maurizio Fusari and Filomena Di Antonio at Ospedale 
Santa Maria delle Croci, Ravenna, Italy. We also thank Dr. Antonio Perez for his 
help in the study conception and writing of the protocol and Laurie Girard for 
the coordination of this study.
Authors’ contributions
JP, PE and BF were involved in the conception and the design of the study. II 
performed the statistical analyses. JP, PE, BF, FR, II and TD analyzed the data 
and wrote the manuscript. All authors read and approved the final manuscript.
Funding
The study was fully financed by Abionic SA (Epalinges, Switzerland; www. 
abion ic. com), developer and manufacturer of the abioSCOPE®, a point‑of‑care 
CE‑marked in vitro diagnostic device that uses proprietary nanofluidic tech‑
nology to measure pancreatic stone protein. Fabien Rebeaud was involved in 
study design and writing of the manuscript.
Availability of data and materials
All data generated or analyzed during this study are included in this published 
article and its additional files.
Declarations
Ethics approval and consent to participate
Approval was obtained from the ethics committees of all participating sites. 
The study has been registered at ClinicalTrials.gov (no. NCT03474809). Written 
informed consent to participation and any study‑related assessment was 
obtained from all patients before their inclusion in the study. Written informed 
consent was obtained according to the specific requirements of each center’s 
ethics committee.
Consent for publication
N/A. The data presented are anonymized, so consent for publication is not 
required.
Competing interests
Irina Irincheeva is affiliated with CTU Bern, University of Bern, which has a staff 
policy of not accepting honoraria or consultancy fees. However, CTU Bern is 
involved in design, conduct, or analysis of clinical studies funded by not‑for‑
profit and for‑profit organizations. In particular, pharmaceutical and medical 
device companies provide direct funding to some of these studies. For an 
up‑to‑date list of CTU Bern’s conflicts of interest see http:// www. ctu. unibe. 
ch/ resea rch/ decla ration_ of_ inter est/ index_ eng. html. Pierre‑François Dequin 
declares that his institution (Centre Hospitalier Régional Universitaire de Tours, 
Tours, France) received grants for the inclusion of patients in the study. Bruno 
François declares receiving consultancy fees from Abionic. The other authors 
declare that they have no conflicts of interest.
Author details
1 Service des soins intensifs, Hôpitaux Universitaires de Genève, Geneva, 
Switzerland. 2 Medical‑Surgical Intensive Care Unit, Inserm CIC 1435 and UMR 
1092, Dupuytren Teaching Hospital, Limoges, France. 3 Service of Intensive 
Care Medicine, Lausanne University Hospital and University of Lausanne, 
Lausanne, Switzerland. 4 Unità Operativa Anestesia e Rianimazione, Ospedale 
Infermi Rimini, AUSL della Romagna, Rimini, Italy. 5 Unità di Terapia Intensiva, 
Azienda Ospedaliera di Perugia, Perugia, Italy. 6 Médecine Intensive, Réanima‑
tion, Centre Hospitalier Régional Universitaire de Tours, Tours, France. 7 Service 
de Réanimation Médico Chirurgicale and USC, Centre hospitalier Le Mans, Le 
Mans, France. 8 Universitätsklinik für Intensivmedizin, Inselspital, Bern Univer‑
sity Hospital, University of Bern, Bern, Switzerland. 9 Terapia Intensiva, Ospedale 
Santa Maria delle Croci, Ravenna, Italy. 10 Division of Critical Care and National 
Institute for Health Research University College London Hospitals Biomedical 
Research Centre, University College Hospital, London, UK. 11 Services de soins 
Critiques, Hôpital Lyon‑Sud, Lyon, France. 12 Intensive Care Medicine, Royal 
Surrey County Hospital, Guildford, UK. 13 Department of Critical Care, Guy’s 
and St Thomas’ Hospital, London, UK. 14 Servizio Anestesia e Rianimazione, 
Ospedale San Giovanni Bosco, Turin, Italy. 15 Clinical Trial Unit (CTU) Bern, 
University of Bern, Bern, Switzerland. 16 Abionic SA, Lausanne, Switzerland. 
17 Department of Locomotor System, Centre Hospitalier Universitaire Vaudois, 
Lausanne, Switzerland. 18 Réanimation Polyvalente, CHU Dupuytren, 2 avenue 
Martin Luther King, 87042 Limoges Cedex, France. 
Received: 15 January 2021   Accepted: 13 April 2021
References
 1. Singer M, Deutschman CS, Seymour CW, et al. The third international 
consensus definitions for sepsis and septic shock (Sepsis‑3). JAMA. 
2016;315:801.
 2. Seymour CW, Liu VX, Iwashyna TJ, et al. Assessment of clinical criteria for 
sepsis: for the third international consensus definitions for sepsis and 
septic shock (Sepsis‑3). JAMA. 2016;315:762–74.
 3. Levy MM, Evans LE, Rhodes A. The surviving sepsis campaign bundle: 
2018 update. Intensive Care Med. 2018;44:925–8.
 4. Rudd KE, Johnson SC, Agesa KM, et al. Global, regional, and national 
sepsis incidence and mortality, 1990–2017: analysis for the Global Burden 
of Disease Study. Lancet Lond Engl. 2020;395:200–11.
 5. Husabø G, Nilsen RM, Flaatten H, et al. Early diagnosis of sepsis in emer‑
gency departments, time to treatment, and association with mortality: an 
observational study. PLoS ONE. 2020;15:e0227652.
 6. Vincent J‑L, Sakr Y, Sprung CL, et al. Sepsis in European intensive care 
units: results of the SOAP study. Crit Care Med. 2006;34:10.
 7. Rhee C, Kadri SS, Danner RL, et al. Diagnosing sepsis is subjective and 
highly variable: a survey of intensivists using case vignettes. Crit Care 
Lond Engl. 2016;20:89.
 8. Vijayan AL, Vanimaya N, Ravindran S, et al. Procalcitonin: a promising diag‑
nostic marker for sepsis and antibiotic therapy. J Intensive Care. 2017;5:51.
 9. Keel M, Seifert B, Bimmler D, et al. Pancreatic stone protein is highly 
increased during posttraumatic sepsis and activates neutrophil granulo‑
cytes. Crit Care Med. 2009;37:7.
 10. Llewelyn MJ, Berger M, Gregory M, et al. Sepsis biomarkers in unselected 
patients on admission to intensive or high‑dependency care. Crit Care. 
2013;17:R60.
 11. Klein HJ, Niggemann P, Buehler PK, et al. Pancreatic stone protein predicts 
sepsis in severely burned patients irrespective of trauma severity: a 
monocentric observational study. Ann Surg. 2020. https:// doi. org/ 10. 
1097/ SLA. 00000 00000 003784.
Page 9 of 9Pugin et al. Crit Care          (2021) 25:151  
•
 
fast, convenient online submission
 •
  
thorough peer review by experienced researchers in your field
• 
 
rapid publication on acceptance
• 
 
support for research data, including large and complex data types
•
  
gold Open Access which fosters wider collaboration and increased citations 
 
maximum visibility for your research: over 100M website views per year •
  At BMC, research is always in progress.
Learn more biomedcentral.com/submissions
Ready to submit your research ?  Choose BMC and benefit from: 
 12. Eggimann P, Que Y‑A, Rebeaud F. Measurement of pancreatic stone 
protein in the identification and management of sepsis. Biomark Med. 
2019;13:135–45.
 13. Que Y‑A, Delodder F, Guessous I, et al. Pancreatic stone protein as an early 
biomarker predicting mortality in a prospective cohort of patients with 
sepsis requiring ICU management. Crit Care. 2012;16:R114.
 14. Que Y‑A, Guessous I, Dupuis‑Lozeron E, et al. Prognostication of mortality 
in critically 111 patients with severe infections. Chest. 2015;148:674–82.
 15. García de Guadiana‑Romualdo L, Albaladejo‑Otón MD, Berger M, et al. 
Prognostic performance of pancreatic stone protein in critically ill 
patients with sepsis. Biomark Med. 2019;13:1469–80.
 16. Putallaz L, Bogaard P van den, Laub P, et al.: Nanofluidics drives point‑
of‑care technology for on the spot protein marker analysis with rapid 
actionable results. J Nanomed Nanotechnol. 2019; 10[cited 2021 Jan 
7] Available from: https:// www. longd om. org/ open‑ access/ nanofl uidi 
cs‑ drives‑ point ofcare‑ techn ology‑ for‑ on‑ the‑ spot‑ prote in‑ marker‑ analy 
sis‑ with‑ rapid‑ actio nable‑ resul ts‑ 44440. html
 17. SepNet Critical Care Trials Group. Incidence of severe sepsis and septic 
shock in German intensive care units: the prospective, multicentre INSEP 
study. Intensive Care Med. 2016;42:1980–9.
 18. Shankar‑Hari M, Harrison DA, Rubenfeld GD, et al. Epidemiology of sepsis 
and septic shock in critical care units: comparison between sepsis‑2 and 
sepsis‑3 populations using a national critical care database. Br J Anaesth. 
2017;119:626–36.
 19. Artero A, Zaragoza R, Miguel J. Epidemiology of severe sepsis and septic 
shock. In: Fernandez R, editor. Severe sepsis and septic shock—under‑
standing a serious killer. InTech; 2012.
 20. Lambden S, Laterre PF, Levy MM, et al. The SOFA score‑development, util‑
ity and challenges of accurate assessment in clinical trials. Crit Care Lond 
Engl. 2019;23:374.
 21. Van Breukelen GJP. ANCOVA versus change from baseline: more power in 
randomized studies, more bias in nonrandomized studies [corrected]. J 
Clin Epidemiol. 2006;59:920–5.
 22. Kahan BC. Accounting for centre‑effects in multicentre trials with a binary 
outcome—when, why, and how? BMC Med Res Methodol. 2014;14:20.
 23. Klein HJ, Rittirsch D, Buehler PK, et al. Response of routine inflammatory 
biomarkers and novel Pancreatic Stone Protein to inhalation injury and 
its interference with sepsis detection in severely burned patients. Burns. 
2020; S0305417920303508
 24. Klein Klouwenberg PMC, Ong DSY, Bos LDJ, et al. Interobserver agree‑
ment of Centers for Disease Control and Prevention criteria for classifying 
infections in critically ill patients. Crit Care Med. 2013;41:2373–8.
 25. Lopansri BK, Miller Iii RR, Burke JP, et al. Physician agreement on the diag‑
nosis of sepsis in the intensive care unit: estimation of concordance and 
analysis of underlying factors in a multicenter cohort. J Intensive Care. 
2019;7:13.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in pub‑
lished maps and institutional affiliations.
